<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512274</url>
  </required_header>
  <id_info>
    <org_study_id>OMZIFL3M</org_study_id>
    <nct_id>NCT04512274</nct_id>
  </id_info>
  <brief_title>Skin Protectant Properties of Omeza Collagen Matrix on Damaged Skin</brief_title>
  <official_title>A Single Center Study in 22 Healthy Male and Female Subjects to Investigate the Skin Protectant and Anti-Inflammatory Properties of Omeza Collagen Matrix on Damaged Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeza, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeza, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-blind within subject comparison study conducted to investigate the skin protectant&#xD;
      properties of Omeza Collagen Matrix on damaged skin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">June 5, 2020</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transepidermal Water Loss (TEWL)</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of water evaporation (TWEL) based upon diffusion principle after 24 hour injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transepidermal Water Loss (TEWL)</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessment of water evaporation (TWEL) based upon diffusion principle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transepidermal Water Loss (TEWL)</measure>
    <time_frame>72 hours</time_frame>
    <description>Assessment of water evaporation (TWEL) based upon diffusion principle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transepidermal Water Loss (TEWL)</measure>
    <time_frame>96 hours</time_frame>
    <description>Assessment of water evaporation (TWEL) based upon diffusion principle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>24 hours</time_frame>
    <description>Irritancy Grading on a 0-4 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>48 hours</time_frame>
    <description>Irritancy Grading on a 0-4 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>72 hours</time_frame>
    <description>Irritancy Grading on a 0-4 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>96 hours</time_frame>
    <description>Irritancy Grading on a 0-4 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Transepidermal Water Loss</condition>
  <condition>Erythema</condition>
  <arm_group>
    <arm_group_label>Test Article</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Article</intervention_name>
    <description>Omeza Collagen Matrix</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a healthy male or female, aged 18 years or older.&#xD;
&#xD;
          -  Subject has signed a written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Inadequate precaution or procedure to prevent pregnancy (women of child bearing&#xD;
             potential only).&#xD;
&#xD;
          -  A current skin disease of any type at the test site (e.g. eczema, psoriasis)&#xD;
&#xD;
          -  Heavy alcohol consumption in the opinion of the investigator.&#xD;
&#xD;
          -  A fever in the last 12 hours, prior to the initial patch application.&#xD;
&#xD;
          -  Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive,&#xD;
             haematological, neurological, locomotor or psychiatric disease, which in the opinion&#xD;
             of the Investigator would compromise the safety of the subject.&#xD;
&#xD;
          -  History of malignant disease.&#xD;
&#xD;
          -  Insulin dependent or non-insulin dependent diabetes.&#xD;
&#xD;
          -  Concurrent medication likely to affect the response to the test articles or confuse&#xD;
             the results of the study, i.e. routine high dosage use of antiinflammatory drugs&#xD;
             (aspirin, ibuprofen, corticosteroids).&#xD;
&#xD;
          -  Known sensitivity to the treatment solutions or their constituents including patch&#xD;
             materials.&#xD;
&#xD;
          -  Sensitisation or questionable sensitisation in a Repeat Insult Patch Test.&#xD;
&#xD;
          -  Use of self-tanning lotion on the test area, one week previous to the start of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barrie Drewitt</last_name>
    <role>Principal Investigator</role>
    <affiliation>PCR Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew King</last_name>
    <role>Study Director</role>
    <affiliation>PCR Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princeton Research Corporation</name>
      <address>
        <city>Chelmsford</city>
        <state>Essex</state>
        <zip>CM2 6UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

